文献速递心力衰竭与心肌病心律失常

心尖肥厚型心肌病的基因型与心律失常风险

Genotype and arrhythmic risk in patients with apical hypertrophic cardiomyopathy.
PubMed 文献 · Heart · 2025-08-26

该研究纳入195例接受二代测序的肥厚型心肌病患者,比较心尖型与非心尖型的临床特征和遗传背景。心尖型患者致病性变异较少(20.9% vs 46.9%),主要心血管不良事件风险较低(HR 0.38),但致死性心律失常事件无差异;致病性变异与致死性心律失常事件独立相关(校正HR 2.50)。

要点

  • 心尖型肥厚型心肌病致病性变异比例低于非心尖型(20.9% vs 46.9%)。
  • 心尖型主要心血管不良事件风险较低(HR 0.38,95%CI 0.19–0.75)。
  • 致病性变异是致死性心律失常事件的独立预测因子(校正HR 2.50)。

核心结论

  • 心尖型肥厚型心肌病虽肥厚程度较轻且遗传检出率较低,但并非完全良性。
  • 致病性变异的存在是心律失常风险的重要预测因素,支持对所有肥厚型心肌病患者进行基因检测。

研究设计与样本

  • 研究纳入韩国两个三级中心2017至2024年接受二代测序的195例肥厚型心肌病患者。
  • 比较心尖型与非心尖型肥厚型心肌病的临床特征和遗传易感性。

主要发现

  • 195例患者中67例(34.4%)为心尖型肥厚型心肌病。
  • 心尖型患者诊断年龄更大,最大左心室壁厚度更低。
  • 心尖型致病性变异频率为20.9%,非心尖型为46.9%(p<0.001)。
  • 心尖型主要心血管不良事件发生较少(HR 0.38,95%CI 0.19–0.75),致死性心律失常事件无差异(HR 0.62,95%CI 0.36–1.08)。
  • 致病性变异与致死性心律失常事件独立相关(校正HR 2.50,95%CI 1.44–4.35)。

临床怎么用

  • 心尖型肥厚型心肌病患者也应进行基因检测以评估心律失常风险。
  • 检出致病性变异提示需加强致死性心律失常事件的监测与风险管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Apical hypertrophic cardiomyopathy (HCM) is a rare variant of HCM, often considered to have a benign prognosis. This study aimed to compare the clinical characteristics and genetic predisposition of apical HCM with non-apical HCM. METHODS: We included 195 patients with HCM who underwent next-generation sequencing at two tertiary centres in South Korea (2017-2024). The primary outcome was a composite of lethal arrhythmic events (LAE), including death, ventricular arrhythmia, implantable cardioverter defibrillator (ICD) implantation and appropriate ICD shock. Secondary outcomes included major adverse cardiovascular events (MACE), such as new-onset atrial fibrillation, ischaemic stroke, heart failure hospitalisation, septal reduction therapy or heart transplant. RESULTS: Of the 195 patients, 67 (34.4%) had apical HCM. Patients with apical HCM were older at diagnosis and had lower maximal left ventricular wall thickness compared with non-apical HCM. Disease-causing variants were less frequent in apical HCM (20.9% vs 46.9%, p<0.001). MYBPC3 and MYH7 variants were less common in apical HCM (50.0%) than in non-apical HCM (75.0%). MACE occurred less frequently in apical HCM (HR 0.38, 95% CI 0.19 to 0.75), but no difference was observed in LAE (HR 0.62, 95% CI 0.36 to 1.08). The presence of disease-causing variants was independently associated with LAE (adjusted HR 2.50, 95% CI 1.44 to 4.35). CONCLUSIONS: Although apical HCM is associated with less hypertrophy and lower genetic yield, it is not entirely benign. The presence of disease-causing variants is an important predictor of arrhythmic risk, underscoring the value of genetic testing in all HCM patients, regardless of phenotype.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Jeong JH, Kim H, Hwang SH, et al. Genotype and arrhythmic risk in patients with apical hypertrophic cardiomyopathy. Heart. 2025. PMID: 40194828. doi:10.1136/heartjnl-2024-325218

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。